The treatment of choroidal neovascularizations in age-related macular degeneration using either avastin or lucentis

Klinische Monatsblatter fur Augenheilkunde

Volumn 226, Issue 4, 2009, Pages 294-298

  Valmaggia, C ^a   Haueter, I ^a   Kloos, P ^a   Lang, C ^a   Niederberger, H ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Age related macular degeneration; Anti VEGF; Avastin; Lucentis

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLURRED VISION; CLINICAL ASSESSMENT; ENDOPHTHALMITIS; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; FOREIGN BODY SENSATION; HUMAN; INJECTION; MAJOR CLINICAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; SUBCONJUNCTIVAL HEMORRHAGE; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; UVEITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; MALE; RETINA MACULA DEGENERATION; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; TREATMENT OUTCOME;

EID: 67650129898     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1109298     Document Type: Article

References (18)

1. Bashshur Z F., Haddad Z A., Schakla A et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 2008 145 249-256
2. Bermig J, Tylla H, Jochmann C et al. Angiographic findings in patients with exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2002 240 169-175
3. Bressler N M. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. Arch Ophthalmol 2001 119 198-207
4. Brown D M., Kaiser P K., Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006 355 1432-1444
5. Gragoudas E S., Adamis A P., Cunningham E T. Pegabtanib for neovascular age-related macular degeneration. N Engl J Med 2004 350 2335-2342
6. Heier J S., Boyer D S., Ciulla T A. et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration. Arch Ophthalmol 2006 124 1532-1542
7. Hurwitz H, Fehrenbacher L, Novotny W. Bevacizumab plus irnotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 350 2335-2342
8. Jonas J B., Spandau U H., Rensch F et al. Infectious and non-infectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 2007 2 240-242
9. Klettner A K., Roider J. Comparison of bevacizumab, ranibizumab and pegaptanib in vitro: efficiency and possible additional pathways. Invest Opthalmol Vis Sci 2008 Epub
10. Lynch S S., Cheng C M. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007 41 614-625
11. Moreno S F., Paloma J B. Therapeutic anti-VEGF in age-related macular degeneration: ranibizumab and bevacizumab controversy. Br J Ophthalmol 2008 92 866-867
12. Pilli S, Kotsolis A, Spaide R F. et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008 145 879-882
13. Quiroz-Mercado H, Ustariz-Gonzales O, Martinez-Castellanos M A. et al. Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story. Seminars in Ophthalmology 2007 22 109-125
14. Raftery J, Clegg A, Jones J et al. Ranibizumab versus bevacizumab: modelling cost effectiveness. Br J Ophthalmol 2007 91 1244-1246
15. Rosenfeld P J., Brown D M., Heier J S. et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006 355 1419-1431
16. Rosenfeld P J., Rich R M., Lalwani G A. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006 19 361-372
17. Valmaggia C, Niederberger H, Lang C et al. The treatment of choroidal neovascularisation with intravitreal injections of bevacizumab. Klin Monatsbl Augenheilkd 2008 225 380-384
18. Wu L, Martinez-Castellanos M A., Quiroz-Mercado H et al. Twelve-month safety of intravitreal injections of bevacizumab: results of the pan-american collaborative retina study group. Graefes Arch Clin Exp Ophthalmol 2007 Epub